CELZ-201-DDT for the Treatment of Chronic Lower Back Pain
Trial statusAvailable
Trial phaseNot listed
Trial typeExpanded Access
Biological sexAll
Age18-80
SponsorCreative Medical Technology Holdings Inc
About this trial
CELZ-201-DDT is an investigational (experimental) cell therapy currently being studied for people with degenerative disc disease who have chronic lower back pain.
Eligibility criteria
Qualifiers
Confirmed diagnosis of chronic lower back pain due to degenerative disc disease.
No comparable or satisfactory alternative therapy available. Unable to participate in the ongoing CELZ-201-DDT clinical trial. Informed consent provided.
Disqualifiers
Any medical condition that poses an unacceptable risk or would interfere with treatment safety or evaluation.
Known hypersensitivity to any component of the investigational product.
Contact the Expanded Access Coordinator to confirm eligibility and discuss feasibility.
Complete and submit FDA Form 3926 to the appropriate FDA review division.
Trial design
Treatments tested in this trial
- CELZ-201-DDT
Treatment groups
No treatment groups listed
Locations
Sponsors and collaborators
Source ClinicalTrials.gov